Showing 641 - 660 results of 700 for search '"Loma Linda University"', query time: 0.12s Refine Results
  1. 641
  2. 642
  3. 643
  4. 644
  5. 645
  6. 646
  7. 647
  8. 648
  9. 649
  10. 650
  11. 651

    Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials by Shah ED, Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ

    Published 2023-02-01
    “…Eric D Shah,1 Bruce H Chamberlain,2 Michelle Rhiner,3 Neil E Slatkin,4,5 Nancy Stambler,6 Robert J Israel7 1Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 2Genesis Healthcare, Davenport, IA, USA; 3Department of Family Medicine, Loma Linda University Health, Loma Linda, CA, USA; 4School of Medicine, University of California Riverside, Riverside, CA, USA; 5Medical Affairs, Salix Pharmaceuticals, Bridgewater, NJ, USA; 6Clinical Research, Progenics Pharmaceuticals, Inc., A Subsidiary of Lantheus Holdings, Inc, New York, NY, USA; 7Clinical and Medical Affairs, Bausch Health US, LLC, Bridgewater, NJ, USACorrespondence: Eric D Shah, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH, 03766, USA, Tel +1 603-650-5261, Email eric.d.shah@hitchcock.orgPurpose: To evaluate the efficacy and safety of subcutaneous (SC) methylnaltrexone for opioid-induced constipation (OIC) in patients with and without active cancer.Patients and Methods: We analyzed two randomized, double-blind, placebo-controlled, Phase 3/4 trials (NCT00402038, NCT00672477). …”
    Get full text
    Article
  12. 652
  13. 653
  14. 654
  15. 655
  16. 656
  17. 657
  18. 658
  19. 659
  20. 660